NCT01027858已完成不适用
Role of Exercise on Cognition and Function in Seniors With Vascular Cognitive Impairment: A Randomized Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 1
- 主要终点
- This is a proof-of-concept study. The primary endpoints are: ADAS-Cog
研究概览
简要总结
The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of aerobic-based exercise training for maintaining cognitive function, executive function, and everyday function in adults with mild vascular cognitive impairment.
详细描述
A total of 70 adults diagnosed with Ischaemic Vascular Cognitive Impairment (SIVCI) will be randomized to either a 6 month thrice weekly walking program or usual care. After 6 months of intervention, they will be followed for an additional 6 months. There will be three measurement sessions: baseline, 6 months (end of intervention period); and 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study will specifically recruit individuals who fulfill the diagnostic criteria for SIVCI as outlined by Erkinjuntti and colleagues (1), which requires the presence of both cognitive syndrome (as defined in Section A below) and small vessel ischaemic disease (as defined in Section B below).
- •A. Cognitive Syndrome defined as:
- •Dysexecutive Syndrome: Some impairment in goal formulation, initiation, planning, organizing, sequencing, executing, set-shifting and maintenance, or abstracting.
- •Memory Deficit: Some impairment in recall, relative intact recognition, less severe forgetting, benefit from cues.
- •Progression: Deterioration of A1 and A2 from a previous higher level of functioning that are not per se interfering with complex occupational and social activities.
- •B. Small Vessel Ischaemic Disease defined as:
- •Evidence of relevant cerebrovascular disease by brain imaging (in the last 12 months) defined as the presence of both:
- •i. Periventricular and deep white matter lesions: Patchy areas of low attenuation (intermediate density between that of normal white matter and that of intraventricular cerebro-spinal fluid) or diffuse symmetrical areas of low attenuation with ill defined margins extending to the centrum semiovale plus at least one lacunar infarct (correlating to the white matter grading scale greater than 3 from the Cardiovascular Health Study) (2,3); and ii. Absence of cortical and/or cortico-sub-cortical non-lacunar territorial infarcts and watershed infarcts, haemorrhages indicating large vessel disease, signs of normal pressure hydrocephalus, or other specific causes of white matter lesions (e.g., multiple sclerosis, leukodystrophies, sarcoidosis, brain irradiation, etc).
- •Presence or a history of neurological signs as evidence for cerebrovascular disease such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, dysarthria, gait disorder, extrapyramidal signs consistent with sub-cortical brain lesion(s).
- •In addition, individuals must meet the following inclusion criteria:
- •Montreal Cognitive Assessment (MoCA) (4) score less than 26 at screening;
- •MMSE (5) score of > 20 at screening;
- •Community-dwelling;
- •Lives in Metro Vancouver;
- •Have a caregiver, family member, or friend who interacts with him/her on a weekly basis;
- •Able to comply with scheduled visits, treatment plan, and other trial procedures;
- •Must be able to read, write, and speak English in which psychometric tests are provided with acceptable visual and auditory acuity;
- •Stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine, rivastigmine, memantine, etc.) that is not expected to change during the 12-month study period, or, if they are not on any of these medications, they are not expected to start them during the 12-month study period;
- •Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals;
- •Able to walk independently; and
- •Must be in sufficient health to participate in study's aerobic-based exercise training program. This will be based on medical history, vital signs, physical examination by study physicians, and written recommendation by family physician indicating individual's appropriateness to participate in an aerobic-based exercise training program.
排除标准
- •Absence of relevant small vessel ischaemic lesions on an existing brain computed tomography (CT) or MRI;
- •Diagnosed with another type of dementia (e.g., AD) or other neurological conditions (e.g., multiple sclerosis, Parkinson's disease, etc.) that affects cognition and mobility;
- •At high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level (i.e., Class C of the American Heart Risk Stratification Criteria);
- •Have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility;
- •Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid, etc.); or
- •Individual who plans to participate or is enrolled in a clinical drug trial concurrent to this study.
结局指标
主要结局
This is a proof-of-concept study. The primary endpoints are: ADAS-Cog
时间窗: baseline, 6 months, and 12 months
EXIT-25
时间窗: baseline, 6 months, and 12 months
ADCS-ADL
时间窗: baseline, 6 months, and 12 months
次要结局
- Secondary outcomes of interest include: performance of specific executive processes(baseline, 6 months, and 12 months)
- Physical function(baseline, 6 months, and 12 months)
- Inflammatory biomarkers(baseline, 6 months, and 12 months)
- Serum glucose and lipids. These will be assessed at 6 and 12 months.(baseline, 6 months, and 12 months)
研究者
Teresa Liu-Ambrose
Principal Investigator
University of British Columbia
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain InjuryBrain ConcussionNCT02276079University of Florida39
已完成
不适用
An Investigation Into the Effects of Acute Exercise on Activities of Daily Living and Cognition in Older AdultsPhysical InactivityNCT06085235Ball State University62
已完成
不适用
Effect of Exercise on Cognitive Function and Mental Health in Heroin AddictsUnspecified Symptoms and Signs Involving Cognitive Functions Following Unspecified Cerebrovascular DiseaseHeroin AddictsExecutive FunctionNegative Thinking/AffectNCT05650983Guangzhou Sport University90
招募中
不适用
Physical Exercise for Cognitive Rehabilitation of Patients With Bipolar Affective DisorderBipolar DisorderNCT06560749Beny Lafer72
已完成
不适用
The Mental Activity and eXercise Trial for SeniorsCognitive ImpairmentNCT00522899University of California, San Francisco126